News

Today, Amylyx Pharmaceuticals, Inc. announced that Health Canada has approved ALBRIOZA (AMX0035) under a Notice of Compliance with Conditions (NOC/c). This means the drug will soon be made available and can be marketed in Canada with certain conditions. Health Canada’s…

Toronto – The ALS Society of Canada (ALS Canada) joins the global ALS community in recognizing June as ALS Awareness Month. More than 3,000 Canadians live with amyotrophic lateral sclerosis (ALS), a neuromuscular disease that paralyzes people because the brain is…

TORONTO, May 13, 2022 – Today, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced that Health Canada has accepted its filing of a Supplement to a New Drug Submission (SNDS) for an…

Now more than ever it is important to know the issues that matter to you before you cast your ballot on Thursday, June 2nd , 2022.   ALS Canada reached out to each major political party to get more details about how…

Over the past several years, ALS Canada, together with the ALS community and a coalition of patient groups across Canada, has raised the alarm about the consequences of the proposed changes to Patented Medicine Prices Review Board (PMPRB) regulations for…

Toronto – Investing in specialized training in clinical care and research skills and supporting young minds are two important ways to continue to ensure the advancement of research across all areas related to amyotrophic lateral sclerosis (ALS). The ALS Canada Research…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the March 2022 Research Update, you’ll learn about advancements in our understanding of risk…